Gilenya and Tasigna drive new product growth at Novartis
This article was originally published in Scrip
Executive Summary
Novartis's Gilenya (fingolimod) has had an excellent launch, with sales of the product "outpacing all previous launches in multiple sclerosis" according to the firm. The first oral product for relapsing remitting or relapsing MS, approved by the FDA in October 2010 and by the EMA in March 2011, Gilenya posted sales of $79 million in the second quarter and $138 million for the first half of 2011.